FDA Advisory Panel Recommends Approval Of Remicade Knockoff

An FDA advisory panel approved a knockoff arthritis drug called Remsima from Pfizer Inc. and Celltrion Inc. The drug is the biosimilar version of Amgen's Remicade, which has brought billions of profits for the company.